These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20386529)

  • 21. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trials in journal of clinical oncology.
    Cannistra SA
    J Clin Oncol; 2009 Jul; 27(19):3073-6. PubMed ID: 19451415
    [No Abstract]   [Full Text] [Related]  

  • 23. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 24. Protocol 126 and "The Hutch".
    Nelson RM
    IRB; 2001; 23(3):14-6. PubMed ID: 11789524
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls.
    Abdel-Rahman SM; Reed MD; Wells TG; Kearns GL
    Clin Pharmacol Ther; 2007 Apr; 81(4):483-94. PubMed ID: 17329988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions.
    Wagner LI; Wenzel L; Shaw E; Cella D
    J Clin Oncol; 2007 Nov; 25(32):5058-62. PubMed ID: 17991921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical trial design in hepatocellular carcinoma.
    Johnson PJ; Billingham LJ
    Best Pract Res Clin Gastroenterol; 2005 Feb; 19(1):119-27. PubMed ID: 15757808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
    Thall PF; Wathen JK; Bekele BN; Champlin RE; Baker LH; Benjamin RS
    Stat Med; 2003 Mar; 22(5):763-80. PubMed ID: 12587104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian two-stage designs for phase II clinical trials.
    Tan SB; Machin D
    Stat Med; 2006 Oct; 25(19):3407-8. PubMed ID: 16847890
    [No Abstract]   [Full Text] [Related]  

  • 36. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials referral resource. Multicenter phase I and II trials in adults with high-grade gliomas.
    Kaplan RS; Smiley JK; Cheson BD
    Oncology (Williston Park); 1999 Apr; 13(4):532-3, 537. PubMed ID: 10234703
    [No Abstract]   [Full Text] [Related]  

  • 38. Randomized phase II studies and their ethics.
    Abratt RP; Reece WH; Enas NH; Stephens R
    J Clin Oncol; 2005 Dec; 23(36):9443. PubMed ID: 16361651
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.
    Royston P; Parmar MK; Qian W
    Stat Med; 2003 Jul; 22(14):2239-56. PubMed ID: 12854091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.
    Markman M
    Curr Oncol Rep; 2007 May; 9(3):159-60. PubMed ID: 17430685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.